Small Molecules in Oncology from Emerging Companies: 2021’s IPOs Pt. III

This article is Part 3 of a review series covering all of the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1 provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Part 2 provided an overview of 2021 IPOs by therapeutic area.

This short article takes a deeper look into the 2021 IPOs for conventional small molecules being developed by oncology-focused companies including:

• Companies by asset class of focus and primary indication

• Lead molecules, mechanisms of action, and structures where available

• Development stage at IPO

• IPO proceeds

• A company spotlight